These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33859799)

  • 1. 1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.
    Grob NM; Schibli R; Béhé M; Valverde IE; Mindt TL
    ACS Med Chem Lett; 2021 Apr; 12(4):585-592. PubMed ID: 33859799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
    Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
    Grob NM; Schmid S; Schibli R; Behe M; Mindt TL
    J Med Chem; 2020 May; 63(9):4496-4505. PubMed ID: 32302130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin
    Grob NM; Schibli R; Béhé M; Mindt TL
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
    Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
    Grob NM; Häussinger D; Deupi X; Schibli R; Behe M; Mindt TL
    J Med Chem; 2020 May; 63(9):4484-4495. PubMed ID: 32302139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
    Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
    Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA; Maina T; Krenning EP; de Jong M
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of
    Hörmann AA; Klingler M; Rangger C; Mair C; Joosten L; Franssen GM; Laverman P; von Guggenberg E
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
    Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the Backbone Function of Tumor Targeting Peptides by an Amide-to-Triazole Substitution Strategy.
    Valverde IE; Vomstein S; Fischer CA; Mascarin A; Mindt TL
    J Med Chem; 2015 Sep; 58(18):7475-84. PubMed ID: 26309061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.
    Holzleitner N; Günther T; Daoud-Gadieh A; Lapa C; Wester HJ
    EJNMMI Res; 2023 Jul; 13(1):65. PubMed ID: 37421545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
    J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
    Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
    J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.